Levrier, Claire, Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan, Sadowski, Martin, & Nelson, Colleen (2018) Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells. Cell Cycle, 17(5), pp. 652-668.

This file was downloaded from: https://eprints.qut.edu.au/111850/

© Consult author(s) regarding copyright matters

This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au

Notice: Please note that this document may not be the Version of Record (i.e. published version) of the work. Author manuscript versions (as Submitted for peer review or as Accepted for publication after peer review) can be identified by an absence of publisher branding and/or typeset appearance. If there is any doubt, please refer to the published source.

https://doi.org/10.1080/15384101.2017.1356512
Discovery of Thalicthuberine as a Novel Antimitotic Agent from Nature that Disrupts Microtubule Dynamics and Induces Apoptosis in Prostate Cancer Cells

Claire Levrier\textsuperscript{1,2}, Anja Rockstroh\textsuperscript{1}, Brian Gabrielli\textsuperscript{3}, Maria Kavallaris\textsuperscript{4,5}, Melanie Lehman\textsuperscript{1,6}, Rohan A. Davis\textsuperscript{1,2}, Martin C. Sadowski\textsuperscript{*,1}, and Colleen C. Nelson\textsuperscript{*,1}

\textsuperscript{1}Australian Prostate Cancer Research Centre–Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD 4102, Australia

\textsuperscript{2}Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia

\textsuperscript{3}The University of Queensland Diamantina Institute; Translational Research Institute; Brisbane, QLD 4102, Australia

\textsuperscript{4}Tumour Biology and Targeting Program, Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, NSW 2052, Australia

\textsuperscript{5}ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and Australian Centre for NanoMedicine, UNSW Australia, NSW 2052, Australia

\textsuperscript{6}Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada

ORCID

Claire Levrier: 0000-0003-0439-0176
Anja Rockstroh: 0000-0002-2700-375X
Brian Gabrielli: 0000-0003-3933-1651
Maria Kavallaris: 0000-0003-2309-898X
Melanie Lehman: 0000-0003-0500-2411
Rohan A. Davis: 0000-0003-4291-7573
Martin C. Sadowski: 0000-0002-5267-1442
Abstract

We report for the first time the mechanism of action of the natural product thalicthuberine (TH) in prostate and cervical cancer cells. TH induced a strong accumulation of LNCaP cells in mitosis, severe mitotic spindle defects and asymmetric cell divisions, ultimately leading to mitotic catastrophe accompanied by cell death through apoptosis. However, unlike microtubule-binding drugs (vinblastine and paclitaxel), TH did not directly inhibit tubulin polymerization when tested in a cell-free system, whereas it reduced cellular microtubule polymer mass in LNCaP cells. This suggests that TH indirectly targets microtubule dynamics through inhibition of a critical regulator or tubulin-associated protein. Furthermore, TH is not a major substrate for P-glycoprotein (Pgp), which is responsible for multidrug resistance in numerous cancers, providing a rationale to further study TH in cancers with Pgp-mediated treatment resistance. The identification of TH’s molecular target in future studies will be of great value to the development of TH as potential treatment of multidrug resistant tumors.

Keywords

Thalicthuberine, mitotic inhibitor, microtubule dynamics, tubulin polymerization, prostate cancer
Introduction

Prostate cancer (PCa) is a global health problem in men; it is the second most diagnosed cancer in developed countries and the fifth most common cause for cancer-related death.\(^1\) Metastatic castrate-resistant PCa (mCRPC) remains an incurable disease and a significant public health burden.\(^2\) This emphasizes the need for additional PCa therapies, including drugs that block proven targets but remain unchallenged by known resistance mechanisms.\(^2\) Mitosis plays a key role in cancer progression, as cancer cells have an uncontrolled mitosis and high proliferation rate.\(^3\) Cell division is a highly regulated process and has emerged over the past decades as one of the most efficient targets of cancer chemotherapy.\(^4\) Some inhibitors of key regulators of cell division are currently being assessed in clinical trial. For example, the Polo-like kinase 1 inhibitor Volasertib has shown promising clinical efficacy in a variety of malignancies including acute myeloid leukemia.\(^5\) The Aurora kinase A inhibitor MNL8237 is currently in phase II clinical trial in patients with mCRPC.\(^6\) Yet, inhibiting mitosis using microtubule-targeting drugs is currently the most effective and widely used chemotherapeutic strategy.\(^7\) Microtubule (MT) drugs inhibit MT dynamics at low nanomolar concentrations, which causes defective mitotic spindle organization, leading to a cell cycle arrest in mitosis and cell death. According to their effect at micromolar doses on MT polymerization, MT inhibitors are divided into two classes: MT-stabilizing agents (e.g., taxanes, epothilones, laulimalide, and peloruside A) and MT-destabilizing agents (e.g., vinca alkaloids, nocodazole, colchicine, and maytansine).\(^7\) Docetaxel and cabazitaxel (semi-synthetic analogs of the natural product paclitaxel) are the gold standard to treat mCRPC,\(^2\) while vinorelbine (semi-synthetic analog of the natural product vinblastine) is the treatment used for a variety of cancers, including breast cancer and small cell lung cancer.\(^8,\,9\) However, severe toxicities (such as toxicity on the peripheral nervous system\(^10\)) and development of resistance in patients to current treatments, highlight the need of new therapeutic agents and new mitotic targets.

Here, we present the mechanism of action study of thalicthuberine (TH), a natural product isolated from the Australian endemic tree Hernandia albiflora (Hernandiaceae). TH is a phenanthrene alkaloid with a 1-(2-aminoethyl) side chain, and was previously isolated from a wide range of plants, including Thalictrum thunbergii,\(^11\) Thalictrum simplex,\(^12\) Thalictrum rugosum,\(^13\) Thalictrum delavayi,\(^14\) Platycapnos spicata,\(^15\) and Platycapnos sp.\(^16\) TH was shown to have antimicrobial activity, especially towards Mycobacterium smegmatis and Candida albicans.\(^13\) Here, we provide evidence that this compound arrests malignant human cell lines in mitosis and induces cell death with a mechanism of action that is distinct from classic MT inhibitors. This is the first time that such an activity has been described for TH.
Results

TH is cytotoxic in various malignant and non-malignant human cell lines.

The cytotoxicity of TH (Fig. 1A) was evaluated against a panel of human prostate cell lines (Table 1), including the prostate cancer cell lines LNCaP, C4-2B, DuCaP, and PC-3, and the non-malignant prostate cell lines BPH-1 and WPMY-1 as well as HeLa cervical cancer cells by using a cell viability assay based on metabolic activity. TH inhibited cell viability in different malignant cell lines with similar IC\textsubscript{50} values ranging from 0.7 µM in PC-3 cells to 2.5 µM in HeLa cells (Table 1). TH exhibited a similar cytotoxic potency in two non-malignant but highly proliferative prostate cell lines, BPH-1 (IC\textsubscript{50} = 2.0 µM) and WPMY-1 (IC\textsubscript{50} = 2.7 µM), suggesting that TH inhibits a process that is critical in proliferating cells. We used the known MT-targeting agent vinblastine\textsuperscript{17-19} as positive control, which was equally cytotoxic in proliferating malignant and non-malignant cell lines\textsuperscript{20} (Table 1). The inhibitory effect of TH on cell growth was confirmed by real-time monitoring of cell confluence by time-lapse phase contrast microscopy (IncuCyte), which showed that TH induced a concentration- and time-dependent inhibition of cell proliferation in LNCaP cells (Fig. 1B). Assessment of the image sequence for morphological changes revealed that TH caused a loss of cell-cell contacts, rounded cell bodies, membrane blebbing, which ultimately led to cell disintegration and are typical signs of cell death through apoptosis (Fig. 1B).\textsuperscript{21,22} TH-induced apoptosis was confirmed by live cell analysis of caspase-3/7 enzyme activity by quantitative fluorescence microscopy in LNCaP cells (Fig. 1C). Like vinblastine,\textsuperscript{23} TH significantly increased the number of caspase-3/7 activity-positive LNCaP cells in a concentration-dependent manner after 48 h of treatment (Fig. 1C). Furthermore, like vinblastine and the positive control cytochalasin D (actin inhibitor), TH significantly inhibited the migration of PC-3 cells, as shown by scratch wound assay after 16 h of treatment (Fig. 1D). Taken together, TH reduces cell viability, proliferation and migration, ultimately leading to cell death through apoptosis.

Gene expression profiling of TH-treated LNCaP cells highlights mitotic pathways.

In order to guide the identification of the molecular target of TH, we performed DNA microarray analysis of LNCaP cells treated for 24 h with a 1 × IC\textsubscript{50} dose of TH (batch A) or vehicle (DMSO) and vinblastine (1 × IC\textsubscript{50} dose) as controls. Ingenuity Pathway Analysis (IPA) revealed that equipotent concentrations of both TH and vinblastine caused transcriptional changes relative to vehicle control that relate to the cell functions “microtubule dynamics”, “M (mitosis) phase”, and “alignment of chromosomes”. GOrilla (Gene Ontology enRChment anaLysis and visuaLizAtion tool) analysis revealed that the genes differentially affected by TH and vinblastine are linked to processes like “mitotic cell cycle progress”, “establishment of chromosome localization” or “microtubule-based process” (Fig. 2A and Supplementary Fig. S1). Moreover, a direct comparison between TH and vinblastine revealed that the vast majority of differentially expressed genes
show the same directionality of up- and down-regulation, as summarized by the heatmap of the fold changes (Fig. 2B). The TH-mediated differential expression of critical cell cycle genes (e.g., CDC20, AURKA, CCNB1, and HMMR) was identified by microarray (Supplementary Table S1). We also observed a downregulation of the expression of α-tubulin (TUBA3C, TUBA3D, and TUBA3E), suggesting that TH affects tubulin expression and might alter MT function. The upregulation of CCNB1 and HMMR mRNA expression was confirmed by qRT-PCR, so was that of the mitotic regulators CDC25B and PLK1. (Fig. 2C).

**TH causes a reversible arrest in mitosis leading to asymmetric divisions and cell death**

Planar compounds with similar structure as TH have been shown to interact with DNA via intercalation, leading to DNA damage. To determine whether TH interacts directly with DNA, we measured the DNA melting temperature and displacement of a fluorescent DNA intercalator in a titration experiment with TH (Supplementary Fig. S2A). Yet, TH did change the DNA melting temperature, suggesting that TH does not intercalate or interact with DNA. Furthermore, quantitative analysis of the DNA double-strand break (DSB) marker γH2AX in LNCaP cells revealed that TH did not increase the number of DSBs after 24 h (and 48 h, data not shown) of treatment when compared to control (Supplementary Fig. S2B). Together, these results indicate that TH does not interact with DNA or causes DNA damage via DSBs.

The observed similarities between TH and the mitotic inhibitor vinblastine prompted us to investigate cell cycle progression. Cell cycle analysis by flow cytometry of LNCaP cells revealed that TH led to a significant concentration-dependent increase in the population of cells in the G2-M phase, as well as cell death (sub G0-G1 phase, Fig. 3A) after treatment for 24 h.

In order to distinguish whether TH caused a cell cycle arrest in G2 or mitosis, we measured the number of LNCaP cells expressing the mitosis marker phospho-Ser10 histone 3 protein (PHH3) by quantitative fluorescence microscopy. In a similar fashion as the mitotic inhibitor vinblastine, TH induced a concentration-dependent increase in the number of PHH3-positive LNCaP cells after 24 h of treatment (Fig. 3B), which was detectable as early as 8 h (Fig. 3C). Inspection of the images revealed that TH-treated LNCaP cells displayed morphological hallmarks typical of mitotic cells (cell rounding and condensation of chromatin, Fig. 1B and Supplementary Fig. S3). Notably, like vinblastine, the TH-mediated mitotic block was reversible when cells were temporarily treated for 8 h, washed with fresh media, and left to recover for 16 h (wash-out experiments, Fig. 3C). However, unlike vinblastine, cells treated for a longer period with TH (24 h) before inhibitor removal (recovery for 48 h in fresh media), cell viability was as negatively impacted as when cells were treated continuously for 72 h (Fig. 3D), suggesting that TH’s effect on LNCaP cell after 24 h of exposure became irreversible.
In order to better characterize TH-mediated mitotic arrest, we studied the time cells required for completion of mitosis and fate of mitosis-arrested cells using time-lapse microscopy of HeLa cells expressing H2B-GFP (Fig. 4A). DMSO-treated HeLa cells normally progressed through mitosis with a mean time of 67.4 ± 32.4 min, followed by cytokinesis (87.1% bipolar division leading to two daughter cells, Fig. 4A). HeLa cells treated with TH exhibited a significantly prolonged time in mitosis from 475.4 ± 253.8 min (1.25 µM) to 657.1 ± 203.1 min (5 µM) in a concentration-dependent manner and similar to vinblastine (10 nM: 398.8 ± 270.3 min, 20 nM: 559.8 ± 210.7 min). As shown in Supplementary Videos S2, S3 and Figure 4A, TH-treated cells failed to properly congress and align their chromosomes at the metaphase plate (monopolar and multipolar phenotypes), resulting in a concentration-dependent increase in asymmetric divisions (mostly 3 or 4 daughter cells) or apoptosis.²⁹ HeLa cells that underwent anaphases with completed karyokinesis and cytokinesis (into three or more daughter cells) frequently fused into single multinuclear cells (Fig. 4A, Supplementary Videos S1–S3).³⁰ A similar phenomenon was observed when HeLa cells were treated with vinblastine (Supplementary Videos S1, Fig. 4A).

Furthermore, the cell fate of asymmetrically divided HeLa-H2B-GFP after TH treatment was analyzed by time-lapse microscopy. As depicted in Figure 4B, some first generation daughter cells derived from asymmetric divisions died in an interphase-like state without entering another round of division, whereas other daughter cells died during the next cell cycle round, or went through another round of asymmetric division, after which second generation offspring failed to divide further and died in an interphase-like state.

**The mitotic spindle organization is perturbed by TH**

The above observations that TH causes transcriptional changes to pathways involved in chromosome segregation, mitotic delay and asymmetric cell division prompted us to investigate if TH affects mitotic spindle organization, which is known to cause similar effects when disturbed.³¹ We used immunofluorescence microscopy of PHH3 and α-tubulin expression in LNCaP cells treated for 24 h with 1.25–5 µM of TH to score phenotypic differences and measure the distance between spindle poles in bipolar cells. TH induced a complete loss of cells with normal bipolar spindle organization and metaphase plate alignment of chromosomes [the dominant phenotype of vehicle-treated control cells (DMSO)] and increased levels of MT spindle abnormalities like bipolar spindles with misaligned chromosomes, monopolar and multipolar spindles (Figs. 5A and 5B). Notably, TH-treated LNCaP cells featuring the multipolar spindle phenotype increased in a dose-dependent manner with a concomittant reduction in bipolar spindles with misaligned chromosomes and monopolar spindles (Fig. 5B). Vinblastine generated similar types and frequencies of MT spindle abnormalities as TH (Figs. 5A and B). In addition, TH induced a dose-dependent reduction of the distance...
between spindle poles in cells with bipolar spindles (Fig. 5B). Together, these results demonstrate that TH disrupts the normal organization of mitotic spindles.

**TH reduces cellular tubulin polymer mass**

Mitotic arrest and abnormal mitotic spindle organization are typical phenotypes induced by MT-targeting agents like vinblastine and paclitaxel.\(^{31}\) To determine if TH directly interacts with tubulin and affects tubulin polymerization, we performed a MT assembly assay with purified components in a cell-free system.\(^{32}\) As expected, vinblastine inhibited tubulin polymerization whereas the MT-stabilizing molecule paclitaxel increased polymerization. At all doses tested (25 µM–200 µM), TH did not have an effect on tubulin polymerization (Fig. 6A). To test the possibility that TH might indirectly interfere with MT polymerization, we measured cellular tubulin polymer mass by quantitative immunofluorescent microscopy of cellular α-tubulin staining.\(^{23, 33}\) When used at high doses (7–30 × IC\(_{50}\)), paclitaxel stimulates MT polymerization and vinblastine induces depolymerization of MT.\(^7\) Similarly to vinblastine, TH visibly disrupted the cellular MT network in LNCaP cells, leading to reduced cellular tubulin polymer mass in a dose-dependent manner (Fig. 6B).

MT are highly dynamic protein structures that grow and shrink very rapidly. The rate of polymerization (growth) and of depolymerization (shortening) of polymers is used to describe MT dynamics. Because they interact with MT and cause their depolymerization, MT destabilizing agents like vinblastine are known inhibitors of MT dynamics.\(^{17}\) To test if TH has an effect on MT dynamics, we treated HeLa cells expressing the end-binding protein (EB1-GFP) with TH and tracked EB1 comets using real-time spinning disk microscopy. EB1 is a protein that binds to the plus end of the growing MT but dissociates during the depolymerization phase.\(^{34}\) Hence, EB1 is a useful tool to track polymerizing MTs and measure changes to MT dynamics.\(^{35}\) TH visibly disrupted directional MT growth, as exemplified by maximum intensity projections of the EB1 comet time-lapse sequences (Fig. 6C and Supplementary Videos S4). Quantitative analysis of the time-lapse videos showed that TH significantly reduced the displacement length of the EB1 tracks in a concentration-dependent manner when compared to vehicle control (Fig. 6C).

Taken together, the above results suggest that, in our experimental conditions, TH disrupted MT dynamics and induced destabilization of the cellular MT network in cells via a mechanism that does not involve direct interaction of TH with tubulin and might involve tubulin associated factors.
Mitotic arrest mediated by TH is phenotypically different to inhibitors of Aurora A kinase and Polo-like kinase-1

Aurora kinase A (Aurora A) and Polo-like kinase 1 (Plk1) are critical regulators of mitosis, and their inhibition has been shown to cause defective spindle organization. Immunofluorescence microscopy revealed that the Aurora A inhibitor MNL8237 alone or in combination with TH strongly suppressed the distinct Aurora A staining at the spindle poles which was visible in LNCaP cells treated with vehicle, vinblastine or TH (Fig. 7A). Furthermore, quantitative analysis of PHH3 staining revealed that LNCaP cells treated with MNL8237 or the combination of TH and MNL8237 yielded less PHH3-positive cells and round cells with condensed DNA than single agent treatment with TH (Fig. 7B). Serine 10 of Histone H3 is a specific target site of Aurora B for phosphorylation, and MNL8237 has been shown to inhibit Aurora B activity, providing a likely explanation for the loss of PHH3 staining in cells treated with MNL8237.

Treatment of LNCaP cells with the Plk1 inhibitor BI2536 induced the formation of monopolar spindles often with dispersed chromosomes at the cell periphery (Fig. 8A). As described in Figure 5, TH treatment resulted in cells with monopolar and multipolar spindles and well congressed chromosomes. The combination of TH or vinblastine with BI2536 produced largely cells with monopolar spindles and dispersed chromosomes (Fig. 8A). Time-lapse microscopy of HeLa cells expressing H2B-GFP showed that cells treated with both compounds significantly delayed mitosis (TH: 523.2 ± 218.1 min and BI2536: 456.3 ± 181.3 min, Fig. 8B). Finally, quantitative assessment of the HeLa H2B-GFP cell fate after single or combination treatment indicated that BI2536 alone or together with TH caused 100% cell death of HeLa H2B-GFP cells, whereas TH predominantly resulted in asymmetric cell division and only 24.8% cell death (Fig. 8B).

Taken together, the different morphological phenotypes induced by MNL8237 and BI2536 strongly suggests that TH does not target Aurora A or Plk1 and that the activity of TH’s target is critical in mitosis after that of both kinases.

Tubulin mutations, MT alterations and overexpression of P-gp do not confer resistance to TH

Despite the success of MT inhibitors in the clinic, patients develop resistance to treatments. Next, we tested if TH is affected by known resistance mechanisms that reduce cytotoxicity of vinca alkaloids and 2-methoxyestradiol (2ME2). The human T-cell acute lymphoblastic leukemia cell lines CEM/2ME2-14.4R and CEM/2ME2-28.8R cells have acquired βI-tubulin mutations in the colchicine binding pocket, making them resistant to 2ME2, as shown by the resistance factors (RF) of 17.9 and 29.2, respectively, when compared to the parental CEM line (Table 2 and Fig. 9A). The vincristine-resistant CEM/VCR-R cells (RF = 12,400, Table 2 and Fig. 9A) have acquired multiple MT alterations (e.g. mutations in βI-tubulin, altered expression of β-tubulin isotypes) and overexpression of P-glycoprotein (P-gp), thereby rendering cells multidrug-
resistant to non-MT-targeting inhibitors such as doxorubicin, daunorubicin, actinomycin D, and tetracycline. As shown in Table 2 and Figure 9A, the cytotoxic potency of TH remained largely unaffected in all three resistant cell lines when compared to parental cells (RF: CEM/2ME2-14.4R = 2.2, CEM/2ME2-28.8R = 1.7, CEM/VCR-R = 7.7). Consistent with a 7.7-fold decrease in cytotoxicity, a 6 to 12-fold higher dose of TH (5-10 µM versus 60 µM) was required to induce similar levels (~40%) of caspase 3/7 activity (apoptosis) in VCR-R cells (Fig. 9B). For comparison, a 2000-fold higher dose of vincristine was required in VCR-R cells when compared to parental cells (Fig. 9B). To study the implication of the P-gp in the observed resistance of CEM/VCR-R cells to TH, the multidrug efflux pump was inhibited with verapamil. VCR-R cells were almost completely re-sensitized to doxorubicin (RF = 2.0) and TH (RF = 2.3) when co-treated with verapamil, indicating that the observed modest resistance to TH (RF = 7.7) was P-gp mediated and that TH was potentially a weak substrate of P-gp (Table 2 and Fig. 9A).

Taken together, resistance mechanisms induced by chronic treatment with vinca alkaloids or 2ME did not confer cross resistance to TH, highlighting the potential of TH as second line treatment.

Discussion

In this work we investigated the mechanism of action of TH, a natural product isolated from the Australian endemic plant Hernandia albiflora. We provided evidence that this small molecule inhibitor is a novel anti-mitotic agent in prostate and cervical cancer cells and that TH evades clinically relevant resistance mechanisms, which render MT inhibitors and other chemotherapeutic drugs inefficient. This is the first report of a detailed mechanism of action study for TH.

In a similar fashion as MT-targeting agents (stabilizers and destabilizers), TH anti-proliferative action at low concentration was mainly due to a mitotic block at the metaphase-anaphase transition. Cells exhibited aberrant mitotic spindles, inhibition of chromosome congression induced by suppression of MT dynamics, and ultimately cell death. We also observed that a large proportion of cells underwent asymmetric divisions into three or four daughter cells, which was TH dose-dependent. Ganem et al. tracked different types of cancer cells (including HeLa cells) using long-term live cell imaging and reported that approximately 3% of HeLa cells went through multipolar divisions and that the resulting mono- and poly-nucleated progenies had several different fates. Most cells would die during mitosis or in an interphase-like state. In rare cases, some cells completed a second round of division, generating mostly unviable daughter cells. Aneja et al. also described an “apoptosis-reluctant population” that underwent aberrant cytokinesis. Some cells died in mitosis while others died after abnormal exit from mitosis. MT-targeting drugs are well-known to induce
mitotic slippage, arrest in G₁ phase and apoptosis.⁴⁹ We hypothesize that TH’s cytotoxicity is mediated through two mechanisms: a short-term effect, by killing cells directly in mitosis and a long-term effect by inducing genetic instability (aneuploidy), ultimately leading to cell death.

Depending on their effect on MTs at high, micromolar concentrations, MT-targeting agents are categorized into MT-stabilizing compounds (e.g. taxanes) and MT-destabilizing compounds (e.g. vinca alkaloids). We observed that TH inhibited MT dynamics in LNCaP and HeLa cells and, like vinblastine, reduced tubulin polymer mass and destabilized the cellular MT network in LNCaP cells. However, in a cell-free assay, TH did not affect tubulin polymerization, raising the possibility that TH does not directly interact with tubulin. The MT7 compound has a planar structure (like TH) and was shown to induce similar phenotypes: aberrant mitotic spindle organization, disruption of cellular MT networks without directly affecting tubulin polymerization in a cell-free assay.⁵⁰ Zhang and co-workers proposed that weak activity (low micromolar IC₅₀ in a panel of cancer cells) or low binding affinity for tubulin prevented a full elucidation of the mechanism of action of this compound.⁵⁰ They designed a series of analogs and reported a compound with a 10-fold increase in activity that was shown to bind to the colchicine binding site and inhibit MT polymerization in a cell-free assay.⁵¹ Ohira et al. described two analogs based on a different scaffold (NP-10 and NP-14) that arrested cells in mitosis with abnormal mitotic spindles, yet, only the most potent compound, NP-14, inhibited tubulin polymerization in a cell-free assay.⁵² The authors observed some differences in the number of centrosomes in cells treated with the two analogs, however, the molecular target(s) of NP-10 remains unknown.⁵²

We addressed the possibility that Aurora A or Plk1 are molecular targets of TH. Plk1 plays a major role in mitosis progression, with a broad range of functions.⁵³ However, the effect of TH (multipolar spindles with congressed chromosomes, asymmetric divisions) was phenotypically different to that of Plk1 inhibitor BI2536 and Aurora A/B inhibitor MNL8237. Combination of the Plk1 inhibitor BI2536 and TH prevented the establishment of the TH phenotype, suggesting that the activity targeted by TH is critical at a later stage of mitosis than Plk1. In a similar manner, combination of TH and the Aurora A/B inhibitor MNL8237 prevented the manifestation of the TH phenotype and suggests that TH’s mitotic target is downstream of Aurora A and B. It is important to note that BI2536 and MNL2536 also prevented the establishment of the vinblastine phenotype in combination treatments.

These results in combination with the disruption of the cellular mitotic network advocate that MT function is the major target of TH action. Cell-free assays as shown for tubulin polymerization are simplified systems with purified components that lack the complexity found in cells, like the absence of MT associated proteins (MAPs) integrating MT function with MT-dependent cellular processes. Indeed, multiple factors can affect
polymerization of MTs in cells, like MAPs, stathmin family proteins, and tubulin modifications, like the deacetylation of α-tubulin by HDAC6, phosphorylation of β-tubulin by Cdk1. Furthermore, Wignall et al. reported a screening of 1561 compounds (purine derivatives) on Xenopus Egg Extract and showed that 15 molecules destabilized MTs without direct binding to tubulin (using quantitative pelleting assay). It is therefore possible that TH indirectly inhibits cellular MT polymerization and dynamics through binding to MAPs or transient tubulin modifications and that such complexity is unlikely present in a cell-free assay system with purified components.

In summary, TH is a novel mitotic inhibitor that destabilizes cellular tubulin polymers and suppresses MT spindle dynamics, resulting in mitotic cell cycle arrest and induction of apoptotic cell death. Understanding clinical relevant resistance mechanisms is a key element in the development of novel, more potent MT-targeted compounds. Importantly, our discovery that TH remains largely unaffected by tubulin alterations or overexpression of P-gp that generate resistance to vinca alkaloids, 2-ME2 and multidrug resistance to non-MT chemotherapeutic drugs (e.g., doxorubicin, daunorubicin, actinomycin D, and tetracycline) provides a strong rationale to further develop TH as potential therapeutic against tumours that display these resistance mechanisms. The relative simple chemical structure and relative ease of total chemical synthesis of TH are another favorable characteristic of this small molecule inhibitor. Therefore, further studies with more potent semi-synthetic analogs are warranted to provide more insights into TH’s target(s), offering a promising starting point for the development of new anti-mitotic therapeutics.

**Isolation of TH**

Thalicthuberine (TH) was isolated from the Australian endemic plant Hernandia albiflora (twigs) using reversed phase HPLC. Hernandia albiflora was part of our pre-fractionated library which was screened for cytotoxic activity toward the LNCaP cell line using a metabolic assay. TH was isolated in 2 batches, and the first batch (batch A, IC$_{50}$ = 17 µM in LNCaP cells) was less active than the second batch (batch B, IC$_{50}$ = 2 µM in LNCaP cells). Both batches were shown to be >95% pure by NMR and LCMS and produced similar phenotypes in LNCaP cells (Supplementary Fig. S3). If not stated otherwise, Batch B was used for the experiments.
Reagents
Vinblastine, verapamil, 2-methoxyestradiol (all Sigma Aldrich), vincristine (Selleckchem), doxorubicin (Selleckchem), paclitaxel (Cytoskeleton), were resuspended in DMSO (Sigma Aldrich) and stock solutions were stored at -20°C.

Cell lines
LNCaP (lymph node metastasis), C4-2B (LNCaP-derivative) and PC-3 (metastatic prostate cancer) cells were obtained from the American Type Culture Collection (ATCC). BPH-1 (human benign prostatic hyperplasia) and WPMY-1 (human prostatic stromal myofibroblast) cells were kind gifts from J. Clements (Queensland University of Technology, Australia). All cells were cultured in phenol-red free RPMI-1640 medium supplemented with 5% FBS (Thermo Fisher Scientific). DuCaP (metastatic prostate cancer) cells were a generous gift from M. Ness (VTT Technical Research Centre of Finland), and cultured in in phenol-red free RPMI-1640 medium supplemented with 10% FBS (Thermo Fisher Scientific). Cells were genotyped at the DNA Diagnostic Center (Cincinnati, USA). HeLa-H2B-GFP (cervical cancer, pBOS-H2BGFP, BD Biosciences) and HeLa-EB1-GFP (EB1-GFP (JB131), Addgene) were made by Professor Gabrielli (University of Queensland, Australia), and were cultured in DMEM medium supplemented with 10% FBS (Thermo Fisher Scientific). Human T-cell acute lymphoblastic leukemia (T-ALL) cell lines CCRF-CEM (CEM) and its drug-resistant sublines CEM/VCR-R, CEM/2ME2-14.4R and CEM/2ME2-28.8R were supplied by Professor Kavallaris (Children’s Cancer Institute, University of New South Wales). Cells were cultures in RPMI-1640 medium supplemented with 5% FBS. All cell lines were kept at 37°C in an atmosphere containing 5% CO₂, maintained in log phase growth and were routinely screened for mycoplasma.

Assessment of cell viability and proliferation
LNCaP (4,000 cells/well), C4-2B (3,000 cells/well), PC-3 (3,000 cells/well), HeLa (2,000 cells/well), DuCaP (15,000 cells/well), BPH-1 (3,000 cells/well), and WPMY-1 (2,000 cells/well) cells were seeded in 96-well plates for 24 h. Cell viability as a function of metabolic activity was measured by alamarBlue endpoint assay (Thermo Fisher Scientific https://www.thermofisher.com/order/catalog/product/DAL1025) after 72 h of treatment following supplier’s instructions. The non-adherent T-ALL cell lines were seeded in 96-well plates (20,000 cells/well) and treated at the same time with the indicated compounds for 72 h. Cell proliferation as a function of cell confluence was evaluated using live-cell imaging (IncuCyte, Essen BioScience) as described before. 61
Cell cycle analysis by flow cytometry
LNCaP cells were plated in 6-well plates (150,000 cells/well) for 24 h and treated with the indicated compounds for 24 h. Cell cycle experiments were conducted as previously described, using 10 µg/ml propidium iodide (Sigma Aldrich http://www.sigmaaldrich.com/catalog/product/sial/p4864?lang=en&region=AU) to stain DNA. Briefly, samples were analyzed on a FACSCanto (BD Biosciences), where 20,000 events were counted after exclusion of cell doublets and polyploid cell populations. DNA histograms were analyzed using ModFit LT software (Verity Software House).

Microarray gene expression profiling
LNCaP were seeded for 24 h in a 6-well plate (150,000 cells/well) and treated with batch A of TH (1 × IC_{50}) or vinblastine (1 × IC_{50}) for 24 h before RNA extraction and processing as described previously (https://www.qiagen.com/fi/shop/rnai/RNeasy-Mini-Kit#orderinginformation). For gene expression profiling, 3–4 repeats of each treatment were analyzed on a custom 180k Agilent oligo microarray (ID032034, GPL16604). Raw data were processed using the Agilent Feature Extraction Software (v10.7) and the LIMMA package in R as described before. Differential expression between treatment and vehicle control (DMSO) was classified based on an FDR-adjusted P value of ≤0.1 and an average fold-change of ≥1.4. Expression data have been submitted to Gene Expression Omnibus (GEO) with the accession number GSE83459. Lists of differentially expressed genes were examined using Ingenuity Pathway Analysis (IPA, Ingenuity Systems Inc.) and GOrilla (Gene Ontology enrichment analysis and visualization tool) for functional annotation and network analysis.

Quantitative real time polymerase chain reaction (qRT-PCR)
RNA samples were generated as described above and processed as reported previously. qRT-PCR was performed with SYBR Green PCR Master Mix (Thermo Fisher Scientific https://www.thermofisher.com/order/catalog/product/4309155) using a 7900HT Fast Real-Time PCR System (Applied Biosystems). Changes in mRNA expression levels were calculated based on the ΔΔCt method, normalized relative to RPL32 expression and expressed as fold-change relative to control (DMSO). Primer sequences (Fwd: forward sequence, Rev: reverse sequence): RPL32 (Fwd: 5’-GCACCAGTCAGACCGATATG-3’, Rev: 5’-ACTGGGCAGCATGTGCTTTG-3’), CCNB1 (Fwd: 5’-AGAGCCATCCTAATTGACTG-3’, Rev: 5’-CAACCAGCTGCAGCATCTTC-3’), CDC25B (Fwd: 5’-AGCGAAACCCCAAAGAGTCAGGT-3’, Rev: 5’-AGCAGCCTCACCGGCATAGACT-3’), PLK1 (Fwd: 5’-TGCCCTACCTACGGACCTTG-3’, Rev: 5’-AAGTTGATCTGCACGCTGCC-3’), HMMR (Fwd: 5’-CTACCTTGCTGCTTCAGCT-3’, Rev: 5’-AGCTGAAGCGCGAAGGTAG-3’).
**Immunofluorescence microscopy**

LNCaP cells were seeded (5,000 cells/well) for 24 h in poly-L-ornithine (Sigma-Aldrich http://www.sigmaaldrich.com/catalog/product/sigma/p4957?lang=en&region=AU) coated optical 96-well plates (ibidi). After the indicated times and concentrations of treatment, cells were fixed with ice-cold methanol for 3 min, incubated in blocking buffer [2% bovine serum albumin (Sigma Aldrich http://www.sigmaaldrich.com/catalog/product/sigma/a9418?lang=en&region=AU) in TBS with 0.1% Triton X-100] for 30 min at room temperature before immunostaining for 1 h at room temperature with primary antibodies. Primary antibodies against phosphor-Ser10 histone H3 (ab5176, Abcam, 1:1,000 http://www.abcam.com/histone-h3-phospho-s10-antibody-chip-grade-ab5176.html) and α-tubulin (DM1A, ab7291, Abcam, 1:500 http://www.abcam.com/alpha-tubulin-antibody-dm1a-loading-control-ab7291.html), and gamma H2AX (phospho S139, kind gift of Associate Professor Derek Richard, Queensland University of Technology, Australia) were used. DNA was counterstained with 1 µg/mL DAPI (4',6-diamidino-2-phenylindole, Sigma Aldrich http://www.sigmaaldrich.com/catalog/product/roche/10236276001?lang=en&region=AU). Cells were imaged using a Cytell or INCell 2200 automated imaging systems (GE Healthcare) and analyzed using the CellProfiler software (Broad Institute, Cambridge, USA) as described before (~4500 cells/treatment). Analysis of spindle organization (~400 cells/treatment) and the distance between spindle poles (~120 cells/treatment) were performed using the Fiji software.

**Washout experiments**

LNCaP cells were seeded as described above in poly-L-ornithine coated plates. Cells were treated with the indicated concentration of compounds for 8 h, 24 h or 72 h. For washout experiments, media was carefully removed after 8 h or 24 h of treatment as indicated and cells were left to recover in fresh media until completion of the experiment.

**Assessment of apoptosis**

The CellEvent Caspase-3/7 reagent (Thermo Fisher Scientific https://www.thermofisher.com/order/catalog/product/R37111) was used to quantitatively evaluate apoptosis in LNCaP, CEM and CEM/VCR-R cells. LNCaP (5,000 cells/well), CEM and CEM/VCR-R were seeded (10,000 cells/well) for 24 h in optical 96-well plate (ibidi) pre-coated with 100 µL of poly-L-ornithine. Apoptosis was assessed after indicated time of treatment using CellEvent Caspase-3/7 reagent following the manufacturer’s instructions. Images were acquired on an INCell 2200 imaging system (GE Healthcare) at 20 × and 40 × magnifications. Image analysis of 3,000 cells/treatment was performed using CellProfiler software. To quantify apoptotic cells, all nuclei (based on DAPI staining) were scored for caspase 3/7-positive and -negative staining.
**Time-lapse microscopy**
HeLa-H2B-GFP cells were seeded (2,000 cells/well) for 48 h in optical 96-well plates (ibidi) and treated with the indicated compounds. Images were acquired every 5 min for 24 h on an Olympus IX81 live-cell microscope using a 10 × objective at 37°C, 5% CO₂, and quantified (time in mitosis and cell fate of ~120 cells/treatment) using Fiji software.

**In vitro tubulin polymerization assay**
MT assembly was studied using the CytoDYNAMIX Screen kit (BK006P; Cytoskeleton Inc. http://www.cytoskeleton.com/bk006p) according to the manufacturer’s instructions. Briefly, purified porcine tubulin proteins (>99% purity) were dissolved in G-PEM buffer containing 80 mM PIPES, 2 mM MgCl₂, 0.5 mM EGTA, 1 mM GTP (pH 6.9) and 19% glycerol at 4°C. The mixture and indicated compounds were transferred into a pre-warmed 96-well plate, and polymerization was monitored using a FLUOstar Omega plate reader at 340 nm every 1 min for 30 min at 37°C.

**Spinning disk microscopy**
HeLa-EB1-GFP cells were seeded (20,000 cells/well) for 48 h in a 35 mm 4-chambers glass bottom dish (Cellvis). After treatment with the specified compounds for 2 h, images were acquired on a Nikon Ti-E Motorized Inverted microscope. Images (60 ×) were taken every second up to 2 min, and EB1 comets were tracked and analyzed using Imaris software (8.2 version).

**DNA interaction studies (melting curve analysis)**
DNA binding/intercalation assay was performed as described by Liberio et al. Briefly, increasing concentration of TH (0.5-1000 µM) were incubated in triplicated with SYBR Green PCR Master Mix (Life Technologies) containing a 151 bp PCR product of the RPL32 gene. DMSO (final concentration of 0.02–1.8%) and DAPI (0.12–1 μM) were used as negative and positive controls, respectively. Melting curves were generated with an Abi 7900HT qRT-PCR machine (Applied Biosystems) and thermal profiles were analyzed with SDS 2.4 software (Applied Biosystems).

**Statistical analysis**
All experiments were performed in technical duplicates or triplicates and repeated at least twice by independent experiments and reported as the mean ± standard deviation of the biological replicates. For all experiments, one-way ANOVA with Dunnett’s multiple comparisons test was used (ns = non-significant, * P <0.05, ** P <0.01, *** P <0.001, **** P <0.0001) unless stated otherwise. Half-maximal inhibitory concentration (IC₅₀) and statistical significance were analyzed using the GraphPad Prism 6 software (GraphPad Software, Inc).
**Abbreviations**

LCMS liquid chromatography/mass spectrometry  
MT microtubule  
NMR nuclear magnetic resonance  
TH thalicthuberine

**Disclosure /Conflict of interest**

The authors declare no conflicts of interest.

**Acknowledgements**

The authors would like to thank Associate Professor Derek Richard for kindly allowing us to use his DeltaVision microscope. We gratefully acknowledge access to the NatureBank (*Hernandia albiflora* plant sample) housed at the Griffith Institute for Drug Discovery.

**Author contribution**

Conception and design: Claire Levrier, Martin C. Sadowski, Maria Kavallaris, Rohan A. Davis, Colleen C. Nelson  
Development of methodology: Claire Levrier, Martin C. Sadowski  
Acquisition of data: Claire Levrier, Martin C. Sadowski, Anja Rockstroh  
Analysis and interpretation of data: Claire Levrier, Martin C. Sadowski, Anja Rockstroh, Brian Gabrielli, Melanie Lehman  
Writing, review, and/or revision of the manuscript: Claire Levrier, Martin C. Sadowski, Brian Gabrielli, Maria Kavallaris, Rohan A. Davis, Colleen C. Nelson  
Administrative, technical, or material support: Martin C. Sadowski  
Study supervision: Martin C. Sadowski, Rohan A. Davis, Colleen C. Nelson
Other [Supply of compound (TH)]: Claire Levrier, Rohan A. Davis

Financial Support

The authors acknowledge the National Health and Medical Research Council (NHMRC) for financial support (Grant APP1024314 to R.A.D.). This work was supported by funding from the Australian Government Department of Health and The Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award (M.C.S., C.C.N). B.G. was supported by an NHMRC Senior Research Fellowship. M.K. is funded by the Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (CE140100036), NHMRC Program Grant (APP1091261) and NHMRC Senior Research Fellowship (APP1058299). C.L would like to thank Griffith University for a Ph.D. scholarship (GUIPRS) and CTx for a PhD Top up scholarship. The Translational Research Institute is supported by a grant from the Australian Government.
References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Esna S, Mathers C, Rebelo M, DM.Parkin, D.Forman, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013.

2. Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol 2012; 4:329-40.

3. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.

4. Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. Cell death & disease 2012; 3:e411.

5. Gjertsen BT, Schoffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015; 29:11-9.

6. ClinicalTrials.gov. A Phase II Trial of MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. 2016.

7. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9:790-803.

8. Guénard D, Guéritte F, Potier P. Produits naturels anticancéreux: La Navelbine® et le Taxotère®. Actual Chim 2003; 263:89-92.

9. Langlois N, Gueritte F, Langlois Y, Potier P. Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids. J Am Chem Soc 1976; 98:7017-24.

10. Park SB, Goldstein D, Krishnan AV, Lin CSY, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 2013; 63:419-37.

11. Fujita E, Tomimatsu T. Studies on the alkaloids of Thalictrum thunbergii DC. II. A quaternary base in the stem and leaves. Chem Pharm Bull (Tokyo) 1958; 6:107-8.

12. Velcheva M, Petrova R, Yansanghii Z. Northalictuberine: a new phenanthrene alkaloid from Thalictrum simplex. Planta medica 1994; 60:485-.

13. Wu W-N, Beal JL, Doskotch RW. Alkaloids of Thalictrum XXX. Eleven Minor Alkaloids From Thalictrum rugosum. J Nat Prod 1980; 43:143-50.
14. Gao C-Y, Ali YE, Sharaf M, Wong LK, Fu EW, Lin F-T, Duah FK, Schiff PL. Alkaloids of *Thalictrum delavayi*. Phytochemistry 1990; 29:1895-7.

15. Blanco OM, Castedo L, Villaverde MC. Alkaloids from *Platycapnos spicata*. Phytochemistry 1993; 32:1055-7.

16. Suau R, Cuevas A, Garcia AI, Rico R, Cabezudo B. Isoquinoline alkaloids from *Platycapnos*. Phytochemistry 1991; 30:3315-7.

17. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by *vinca* alkaloids. Cancer Res 1991; 51:2212-22.

18. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 1992; 102:401-16.

19. Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 1993; 32:1285-93.

20. Serafin AM, Akudugu JM, Bohm L. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status. Urol Res 2002; 30:289-94.

21. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001; 3:339-45.

22. Mills JC, Stone NL, Erhardt J, Pittman RN. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J Cell Biol 1998; 140:627-36.

23. Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells. Mol Cancer Ther 2017; 16:3-15.

24. Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004; 6:158-67.

25. Chen ZF, Shi YF, Liu YC, Hong X, Geng B, Peng Y, Liang H. TCM active ingredient oxoglauicine metal complexes: crystal structure, cytotoxicity, and interaction with DNA. Inorg Chem 2012; 51:1998-2009.

26. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139. J Biol Chem 1998; 273:5858-68.
27. Vanden Bosch A, Raemaekers T, Denayer S, Torrekens S, Smets N, Moermans K, Dewerchin M, Carmeliet P, Carmeliet G. NuSAP is essential for chromatin-induced spindle formation during early embryogenesis. J Cell Sci 2010; 123:3244-55.

28. Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71:496-505.

29. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-37.

30. Stevens FE, Beamish H, Warrener R, Gabrielli B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene 2008; 27:1345-54.

31. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65.

32. Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, et al. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res 2006; 66:951-9.

33. Ovechkina Y, Wagenbach M, Wordeman L. K-loop insertion restores microtubule depolymerizing activity of a “neckless” MCAK mutant. J Cell Biol 2002; 159:557-62.

34. Tirnauer JS, Canman JC, Salmon ED, Mitchison TJ. EB1 targets to kinetochores with attached, polymerizing microtubules. Mol Biol Cell 2002; 13:4308-16.

35. Matov A, Applegate K, Kumar P, Thoma C, Krek W, Danuser G, Wittmann T. Analysis of microtubule dynamic instability using a plus-end growth marker. Nat Meth 2010; 7:761-8.

36. Lénárt P, Petronczki M, Stegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters J-M. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Current biology: CB 2007; 17:304-15.

37. Kesisova IA, Nakos KC, Tsolou A, Angelis D, Lewis J, Chatzaki A, Agianian B, Giannis A, Koffa MD. Tripolin A, a novel small-molecule inhibitor of Aurora A kinase, reveals new regulation of HURP’s distribution on microtubules. PloS one 2013; 8:e58485.
38. Goto H, Yasui Y, Nigg EA, Inagaki M. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes to cells: devoted to molecular & cellular mechanisms 2002; 7:11-7.

39. Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 2013; 37:434-9.

40. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Persky AMDO, Miller TP, Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 2011; 81:881-90.

41. Liaw TY, Salam NK, McKay MJ, Cunningham AM, Hibbs DE, Kavallaris M. Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions. Mol Cancer Ther 2008; 7:3150-9.

42. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61:5803-9.

43. Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. Identification of dual DNA-PK MDRI inhibitors for the potentiation of cytotoxic drug activity. Biochem Pharmacol 2014; 88:58-65.

44. Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to vinca alkaloids independent of P-glycoprotein. Cancer Res 1989; 49:5281-7.

45. Kavallaris M, Madafiglio J, Norris MD, Haber M. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells. Biochem Biophys Res Commun 1993; 190:79-85.

46. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989; 49:5002-6.
47. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460:278-82.

48. Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, et al. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. European journal of cancer (Oxford, England: 1990) 2010; 46:1668-78.

49. Chen J-G, Yang C-PH, Cammer M, Band Horwitz S. Gene Expression and Mitotic Exit Induced by Microtubule-Stabilizing Drugs. Cancer Res 2003; 63:7891-9.

50. Zhang Z, Meng T, He J, Li M, Tong LJ, Xiong B, Lin L, Shen J, Miao ZH, Ding J. MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules. Invest New Drugs 2010; 28:715-28.

51. Zhang Z, Meng T, Yang N, Wang W, Xiong B, Chen Y, Ma L, Shen J, Miao Z-H, Ding J. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. Int J Cancer 2011; 129:214-24.

52. Ohira M, Iwasaki Y, Tanaka C, Kuroki M, Matsu N, Kitamura T, Yukuhiro M, Morimoto H, Pang N, Liu B, et al. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo. Biochimica et Biophysica Acta (BBA) - General Subjects 2015; 1850:1676-84.

53. Barr FA, Sillje HHW, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5:429-41.

54. Bhat KMR, Setaluri V. Microtubule-Associated Proteins as Targets in Cancer Chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research 2007; 13:2849-54.

55. Charbaut E, Curmi PA, Ozon S, Lachkar S, Redeker V, Sobel A. Stathmin Family Proteins Display Specific Molecular and Tubulin Binding Properties. J Biol Chem 2001; 276:16146-54.

56. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. Embo j 2002; 21:6820-31.
57. Fourest-Lieuvin A, Peris L, Gache V, Garcia-Saez I, Juillan-Binard C, Lantez V, Job D. Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1. Mol Biol Cell 2006; 17:1041-50.

58. Wignall SM, Gray NS, Chang YT, Juarez L, Jacob R, Burlingame A, Schultz PG, Heald R. Identification of a novel protein regulating microtubule stability through a chemical approach. Chem Biol 2004; 11:135-46.

59. Kini SV, Ramana MMV. A new convenient synthesis of phenanthrene alkaloids from 1-aryl methyl-1,2,3,4-tetrahydroisoquinolines. Tetrahedron Lett 2004; 45:4171-3.

60. Nimigrawath S, Chaturonrugsamee S. Synthesis of Thalicthuberine. J Chin Chem Soc 2006; 53:443-7.

61. Levrier C, Sadowski MC, Nelson CC, Davis RA. Cytotoxic C20 diterpenoid alkaloids from the Australian endemic rainforest plant Anopterus macleayanus. J Nat Prod 2015; 78:2908-16.

62. Sadowski MC, Pouwer RH, Gunter JH, Lubik AA, Quinn RJ, Nelson CC. The fatty acid synthase inhibitor Triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget 2014; 5:9362-81.

63. Sieh S, Taubenberger AV, Rizzi SC, Sadowski M, Lehman ML, Rockstroh A, An J, Clements JA, Nelson CC, Hutmacher DW. Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. PloS one 2012; 7:e40217.

64. Liberio MS, Sadowski MC, Davis RA, Rockstroh A, Vasireddy R, Lehman ML, Nelson CC. The ascidian natural product eusynstylamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells. Oncotarget 2015; 6:43944-63.

65. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43:e47.

66. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009; 10:1-7.

67. Liberio MS, Sadowski MC, Soekmadji C, Davis RA, Nelson CC. Differential effects of tissue culture coating substrates on prostate cancer cell adherence, morphology and behavior. PloS one 2014; 9:e112122.
68. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006; 7:1-11.

69. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Meth 2012; 9:676-82.
Table 1: Measurement of cytotoxic activity of TH against a panel of human malignant and non-malignant cell lines of the prostate and cervix

| Compounds | LNCaP  | C4-2B  | DuCaP  | PC-3   | HeLa   | BPH-1  | WPMY-1 |
|-----------|--------|--------|--------|--------|--------|--------|--------|
| TH (µM)   | 2.0 ± 0.6 | 1.0 ± 0.2 | 1.3 ± 0.1 | 0.7 ± 0.1 | 2.5 ± 0.5 | 2.0 ± 0.7 | 2.7 ± 0.1 |
| Vinb (nM) | 3.2 ± 0.1 | 2.4 ± 0.2 | 3.7 ± 0.7 | 2.5 ± 0.4 | 11.6 ± 4.2 | 3.8 ± 0.6 | 4.2 ± 0.6 |

*Cytotoxicity (IC$_{50}$) of TH was measured after 72 h of treatment (alamarBlue) in the indicated cell lines (n = 3, mean ± SD). Vinblastine was used as positive control.*
Table 2: Cytotoxicities of TH remains largely unaffected in cell lines with resistance to microtubule inhibitors and express multidrug resistance.

| Compound      | CEM               | CEM/2ME2-14.4R     | CEM/2ME2-28.8-R |
|---------------|-------------------|--------------------|-----------------|
|               | IC₅₀ (µM)         | IC₅₀ (µM)          | RF              |
| TH            | 2.1 ± 0.7         | 4.7 ± 1.0          | 2.2             |
| 2ME2          | 0.8 ± 0.2         | 14.3 ± 0.5         | 17.9            |
| CEM           | IC₅₀ (µM)         | IC₅₀ (µM)          | RF              |
| TH            | 2.1 ± 0.7         | 16.2 ± 3.4         | 7.7             |
| Vinc          | 0.0005 ± 0.0      | 6.2 ± 1.4          | 12,400          |
| Dox           | 0.1 ± 0.0         | 2.5 ± 0.2          | 25.0            |
| Verap         | >10,000           | >10,000            | -               |
| Vinc + verap  | 0.001 ± 0.0       | 0.08 ± 0.04        | 80.0            |
| TH + verap    | 1.8 ± 0.2         | 4.1 ± 0.1          | 2.3             |
| Dox + verap   | 0.1 ± 0.1         | 0.2 ± 0.1          | 2.0             |

Cytotoxicity (IC₅₀) of TH, vincristine (Vinc), 2-methoxyestradiol (2ME2), doxorubicin (Dox), and verapamil (verap) was measured (72 h, alamarBlue) in indicated cell lines (n = 3, mean ± SD). The resistance factor (RF) expresses the quotient IC₅₀ (drug-resistant cell line)/IC₅₀ (parental CEM cell line).
Figure 1: TH inhibits proliferation, migration, and induces apoptosis in PCa cells. (A) Chemical structure of thalicthuberine (TH). (B) Analysis of real-time proliferation, as a function of cell confluence (IncuCyte) of TH treated LNCaP cells. DMSO (vehicle) and vinblastine (Vinb) were used as controls (n = 3, mean ± SD, a representative experiment of three independent repeats is shown). Phase contrast images for DMSO, TH (2.5 µM), and Vinb (25 nM) treatments are shown for the indicated time points (top right panel), showing visibly less cells and signs of apoptotic cell death (membrane blebbing, rounded cell bodies) in TH and vinblastine treated cells. Scale bar = 100 µm. (C) Live assessment by microscopy and quantitative image analysis of caspase-3/7 activity in TH- and vinblastine-treated LNCaP cells after 48 h of treatment. Both TH and vinblastine induced apoptosis in a concentration-dependent manner (left panels, n = 3, mean ± SD). Representative images of LNCaP cells. Right panel, merged image: DNA (blue), Caspase 3/7: CellEvent...
Caspase-3/7 substrate (pink), scale bar = 20 µm. (D) Evaluation of cell migration of TH-treated PC-3 cells. Wound closure was measured by live-cell imaging (IncuCyte) after 16 h of treatment with vehicle control (DMSO), TH, vinblastine (Vinb) or the positive control cytochalasin D (Cytoch) (left panel, n = 2, mean ± SD). Representative wounds after treatment with DMSO, TH and cytochalasin D are shown (right panel).
Figure 2: Treatment of LNCaP cells with TH leads to deregulation of mitotic processes. (A) GeneOntology analysis of DNA microarray data (GOrilla) revealed “microtubule-based process”, “cell cycle process”, and “mitotic cell cycle process” as top enriched molecular pathways within the set of differentially expressed genes after 24 h of TH treatment (1 × IC₅₀) in LNCaP cells. (B) Heatmap depicting the fold changes of genes differentially expressed (P value ≤0.1, fold-change of ≥1.4) in LNCaP cells after 24 h treatment with TH (1 × IC₅₀) in LNCaP cells.
IC50) or vinblastine (Vinb, 1 × IC50). Red indicates up-regulation. The darker the shade of color, the higher the fold-change of expression. (C) Validation of differential expression of critical cell cycle genes by qRT-PCR (n = 3, mean ± SD) in LNCaP cells treated for 24 h with TH (1 × IC50) or vinblastine (Vinb, 1 × IC50), confirming their up-regulation.
Figure 3: TH causes accumulation of cells in mitosis (A) Cell cycle was analyzed by flow cytometry. TH arrests LNCaP cells in the G2-M phase in a concentration-dependent manner after 24 h (upper left panel). DMSO and vinblastine were used as controls (left panel, n = 4, mean ± SD, statistical data in Supplementary Table S2). Representative histograms for DMSO and TH are shown (lower panel). TH treatment of LNCaP cells (24 h) leads to cell death (upper right panel, sub G0-G1 cell population, n = 3, mean ± SD) (B)
Quantitative immunofluorescence microscopy of PHH3 expression (mitosis marker) revealed that TH and vinblastine caused a concentration-dependent increase of PHH3-positive LNCaP cells after 24 h (n = 3, mean ± SD). (C) Immunofluorescence microscopy coupled with automated image analysis (CellProfiler) was used to quantify PHH3-positive (mitotic) LNCaP cells (~3,000 cells/treatment) after the indicated treatment conditions (n = 2, mean ± SD). TH (1.25-10 µM) and vinblastine (10 and 20 nM) induced a significant increase in PHH3-positive cells when treated for after 8 h (blue bars). Longer treatment (24 h, orange bars) further increased the proportion of PHH3-positive cells. Removal of TH (1.25 and 2.5 µM) and vinblastine (10 and 20 nM) after 8 h of treatment followed by 16 h of recovery decreased the number of PHH3-positive cells to levels seen in vehicle control (DMSO). Two-ways ANOVA with Sidak’s multiple comparisons test was used (ns = non-significant, *** P < 0.001, **** P < 0.0001; blue label = statistical comparison to DMSO 8 h). (D) LNCaP cells were subjected to the same treatment modalities as described in C, and cell viability was measured after 72 h (alamarBlue, n = 2, mean ± SD). Intermittent treatment with TH (24 h) did not significantly reduced cell viability compared to continuous treatment (72 h). Two-ways ANOVA with Sidak’s multiple comparisons test was used (ns = non-significant, ** P < 0.01, *** P < 0.001).
Figure 4: TH induced mitotic arrest is leading to asymmetric cell division and cell death. (A) Quantitative analysis of images acquired by time-lapse microscopy (Olympus IX81, 10 x, 1 image/5 min for 24 h) showed that TH and vinblastine significantly increased the time HeLa-H2B-GFP cells spent in mitosis (left panel). The cell fate (bipolar division, asymmetric division or apoptosis) was quantitatively assessed after 24 h of...
treatment (right panel, n = 2, mean ± SD). Representative images of cells treated with TH (2.5 µM) and DMSO. Black arrows indicate cells displaying signs of asymmetric division and fusion. Red arrows point at cells dying. Scale bar = 20 µm. (B) Tracking of cell fate of cells that underwent asymmetric division. Representative image of HeLa-H2B-GFP cells treated with TH (2.5 µM) and tracked for 106 h using real-time live-cell imaging (IncuCyte 10 ×, 1 image/2 h for 144 h). White arrows indicate cells going through asymmetric division, fusion and dying in mitosis. Red arrows mark cells that die in an interphase-like state after two consecutive rounds of asymmetric division separated by a cell fusion event. Yellow arrows indicate cells going through asymmetric division, fusion and dying in an interphase-like state. Scale bar = 50 µm. For more details, see Videos 1–3.
Figure 5: TH disrupts the mitotic spindle organization. (A) TH and vinblastine-treated LNCaP cells (24h) were subjected to immunofluorescence microscopy of α-tubulin (green) and PHH3 (red) with an INCell 2200 automated imaging (20 ×). Representative images (top panel) of abnormal metaphase alignments of chromosomes (PHH3 staining, red) and spindle pole organization (α-tubulin staining, green) are shown (scale bar = 10 µm). (B) Quantification by scoring phenotypic differences (bottom left panel, ~400 cells/treatment)
and measuring the distance between spindle poles (bottom right panel, ~120 cells/treatment, yellow line) in bipolar cells are based on α-tubulin and PHH3 staining (n = 3, mean ± SD).
Figure 6: TH treatment leads to reduced cellular tubulin polymer mass and shortened MT tracks. (A) TH did not affect tubulin polymerization in a cell-free system, while vinblastine (Vinb) inhibited and paclitaxel (Paclit) stimulated polymerization. A representative experiment (n = 3) is shown. (B) High-dose treatment of LNCaP cells (24h) with TH or vinblastine reduced cellular tubulin polymer mass, while paclitaxel increased tubulin polymer mass (top right panel), as shown by quantitative immunofluorescence microscopy of the
mean intensity fold-change of α-tubulin relative to DMSO control (n = 3, mean ± SD). Representative images are shown (lower panel), illustrating disrupted cytoplasmic MT networks. Scale bar = 10 µm. (C) HeLa-EB1-GFP cells treated with TH or vinblastine (2 h) were imaged by spinning disk microscopy. EB1 comets were tracked and analyzed, and mean fold-change of displacement length of EB1 tracks was calculated relative to DMSO control. Like vinblastine, TH inhibited the growth of MTs in HeLa cells, as shown by reduced EB1 tracks in maximum intensity projections of EB1 comets (scale bar = 10 µm). For more details, see Videos 4–6.
Figure 7: The mitotic inhibitors MNL8237 (Aurora A inhibitor) and TH generate different phenotypes. (A) LNCaP cells treated with TH and the Aurora kinase A inhibitor MNL8237 for 24 h were subjected to immunofluorescence microscopy of Aurora A (green) and DNA (blue) with a DeltaVision Elite microscope (60×). As controls, cells were treated with the Plk1 inhibitor BI2536, vinblastine (Vinb, 10 nM), or vehicle.
control (DMSO). MNL8237 inhibited localization of Aurora A at the spindle poles, which was not affected by TH or BI2536. Representative images are shown. Scale bar = 10 µm. (B) Immunofluorescence microscopy coupled with automated image analysis was used to quantify PHH3-positive LNCaP cells after the indicated treatment conditions (left panel, n = 2, mean ± SD). Combination of TH and MNL8237 or vinblastine (Vinb) and MNL8237 generated the same phenotypes as MNL8237 treatment alone, including a loss of PHH3 expression. Representative images are shown (left panel), DNA (blue), α-tubulin (green), and PHH3 (pink). Mitotic cells are indicated by an arrow (strong nuclear condensed chromatin and a round cell morphology). Scale bar = 20 µm.
Figure 8: The Plk1 inhibitor BI2536 and TH generate different phenotypes. (A) LNCaP cells treated with two mitotic inhibitors, TH or BI2536 (Plk1 inhibitor), for 24 h were subjected to immunofluorescence microscopy of α-tubulin (green) and PHH3 (red) with a DeltaVision Elite microscope (60 ×, upper panel, scale bar = 10 µm) or an INCell 2200 (20 ×, lower panel, scale bar = 20 µm). As controls, cells were treated with vinblastine.
(Vinb, 10 nM) or vehicle control (DMSO). BI2536 inhibited spindle pole organization and predominantly generated cells with monopolar spindles and peripheral chromosome configurations, while TH generated heterogeneous spindle pole abnormalities (monopolar, bipolar and multipolar) with visibly congressed chromosomes. Cells treated with a combination of TH and BI2536 exhibited the BI2536-like phenotype. Representative images are shown, scale bar = 20 µm. (B) Quantification of time-lapse microscopy showed that TH and BI2536 increased the time HeLa-H2B-GFP cells spend in mitosis (left panel). The cell fate after 24 h (bipolar division, asymmetric division or cell death) was quantitatively assessed and showed that BI2536 alone or in combination with TH exclusively induced cell death, while TH as single treatment caused asymmetric divisions and cell death (right panel, ~100 cells/treatment, n = 2, mean ± SD). One-way ANOVA with Turkey’s multiple comparisons test was used (ns = non-significant, ** P < 0.01, **** P < 0.0001). See Video 3 for more details.
Figure 9: TH is insensitive to resistance mechanisms induced by MT inhibitors (vinca alkaloids and 2ME2). (A) Parental cells CEM (CEM), 2-methoxyestradiol (2ME2) resistant cell lines CEM/2ME2-14.4R (14-4) and CEM/2ME2-28.8R (28-8), and the vincristine (Vinc) resistant cell line CEM/VCR-R (VCR-R) were treated...
with 2ME2, Vinc, or TH for 72 h and cell viability was measured using a metabolic assay (alamarBlue, n = 3). Results were expressed as resistance factor (RF), which was calculated from the quotient of IC$_{50}$ (drug-resistant cell line) and IC$_{50}$ (parental CEM cells). TH activity remained largely unaffected in all three resistant cell lines when compared to CEM parental cells. The involvement of the P-glycoprotein (P-gp) in resistance observed in the CEM/VCR-R (VCR-R) cell line, was assessed by co-treatment with the P-gp inhibitor verapamil (verap). As control, cells were treated with the P-gp substrate doxorubicin (Dox). Co-treatment with verapamil almost completely re-sensitized CEM/VCR-R cells to TH and doxorubicin, suggesting that TH activity is not affected by mutation in the vinca alkaloid pocket on tubulin. (B) Live assessment by microscopy and quantitative image analysis of caspase-3/7 activity in TH- and vincristine-treated CEM and CEM/VCR-R (VCR-R) cells after 24 h of treatment (n = 3, mean ± SD). Similar doses of TH were necessary to induce apoptosis in both cell lines, while 2000-fold higher dose of vincristine was required in VCR-R cells when compared to CEM cells.